MeiraGTx Holdings plc (MGTX)
Automate Your Wheel Strategy on MGTX
With Tiblio's Option Bot, you can configure your own wheel strategy including MGTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MGTX
- Rev/Share 0.3387
- Book/Share -0.501
- PB -16.566
- Debt/Equity -0.061
- CurrentRatio 0.2235
- ROIC -4.2007
- MktCap 668074379.0
- FreeCF/Share -1.4514
- PFCF -5.6865
- PE -3.9829
- Debt/Assets 0.0131
- DivYield 0
- ROE -10.6547
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MGTX | H.C. Wainwright | -- | Buy | -- | $20 | Nov. 24, 2025 |
| Initiation | MGTX | Raymond James | -- | Strong Buy | -- | $29 | Oct. 21, 2025 |
News
Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and central nervous system disorders, among other therapeutic indications, today announced that Samuel Waksal, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore HealthCONx Conference.
Read More
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Negative
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.54 per share a year ago.
Read More
MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential
Published: November 12, 2025 by: Seeking Alpha
Sentiment: Positive
MeiraGTx Holdings plc secures a transformative partnership with Eli Lilly, granting worldwide rights to its AAV-AIPL1 gene therapy for LCA4. MGTX receives $75 million upfront, up to $400 million in milestones, and tiered royalties, strengthening its financial position and reducing near-term dilution risk. The company's riboswitch technology and multiple collaborations, including with Johnson & Johnson and Hologen, highlight its innovation and diversified pipeline.
Read More
Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
Published: November 10, 2025 by: Reuters
Sentiment: Positive
MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder that causes severe vision loss from birth.
Read More
MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last?
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates
Published: August 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.76 per share a year ago.
Read More
3 Promising Genomics Stocks to Keep an Eye On in 2025
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Read More
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Negative
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.77 per share a year ago.
Read More
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regulatory interactions with the FDA, and potential routes to accelerated approval and Priority Review LONDON and NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV-GAD for the treatment …
Read More
MeiraGTx Holdings: Gaining Regulatory Focus
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Positive
MeiraGTx (MGTX) develops gene therapies for ocular diseases, Parkinson's Disease, and xerostomia, with multiple assets in advanced clinical stages showing promising efficacy and safety data. MGTX uses AAV5 capsid vectors and riboswitch technology to deliver gene therapies, aiming for safer and more controlled treatments compared to earlier approaches. Financially, MGTX has a strong cash position bolstered by a $200mn deal with Hologen, providing a substantial runway for continued development.
Read More
About MeiraGTx Holdings plc (MGTX)
- IPO Date 2018-06-08
- Website https://www.meiragtx.com
- Industry Biotechnology
- CEO Alexandria Forbes
- Employees 375